Straits Times Index
3,300.27 +27.55 (+0.84%) Nikkei
38,410.49 +858.33 (+2.29%) Hang Seng
17,154.64 +325.71 (+1.94%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,712.64 +170.35 (+0.26%) CMC Crypto 200
1,439.06 +24.30 (+1.72%)
Harmony Biosciences Holdings, Inc. (HRMY)
After hours:
| Previous close | 29.35 |
| Open | 29.52 |
| Bid | 28.81 x 200 |
| Ask | 28.99 x 100 |
| Day's range | 28.69 - 30.00 |
| 52-week range | 18.61 - 39.26 |
| Volume | |
| Avg. volume | 367,624 |
| Market cap | 1.638B |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | 13.54 |
| EPS (TTM) | 2.13 |
| Earnings date | 30 Apr 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.63 |
PR NewswireHARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on April 30, 2024, at 8:30 a.m. ET to discuss the results.
- PR Newswire
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists with the potential for a best-in-class clinical profile.
- PR Newswire
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (EDS) and behavioral symptoms in patients aged six years and older with Prader-Willi syndrome (PWS).
